Breaking News
July 22, 2018 - Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010
July 22, 2018 - QUT researcher highlights growing impact of non-prescription antibiotics supply in pharmacies
July 22, 2018 - UK health communication researcher seeks solutions for disposing leftover medicine
July 22, 2018 - Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Fidanacogene Elaparvovec
July 22, 2018 - Mutation discovered to protect against Alzheimer’s disease in mice
July 22, 2018 - Researchers reveal how patients in urban areas develop multiple, long-term conditions
July 22, 2018 - Replacing conventional cancer treatment with complementary therapy linked to increased risk of death
July 22, 2018 - Study uncovers molecular key for delaying progression of multiple sclerosis
July 22, 2018 - Availability of athletic trainer in high school reduces injury rates in girls’ sports, shows study
July 22, 2018 - FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
July 22, 2018 - Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases
July 22, 2018 - Physical activity even during exposure to air pollution can reduce risk of heart attack
July 22, 2018 - Scientists discover protein regulator of myelin production
July 22, 2018 - Sleep disturbances associated with higher dementia risk
July 22, 2018 - Scientists move one step further in developing eye drops to treat age-related macular degeneration
July 22, 2018 - Five-Year Stroke Rates Lower After PCI Versus CABG
July 21, 2018 - Alopecia areata – Genetics Home Reference
July 21, 2018 - Study identifies overdose risk factors in youth with substance use disorders
July 21, 2018 - Drug in clinical trials for Parkinson’s disease offers hope for treating heart failure
July 21, 2018 - Coupling free malaria tests with diagnosis-dependent vouchers can improve rational use of ACTs
July 21, 2018 - Sweetness depends on molecular interactions between specific sugars and water in saliva
July 21, 2018 - Muscle fitness is strongly associated with improved rate of ageing in the brain
July 21, 2018 - Resetting E-Prescriptions for Opioids Helps Curb Use: Study
July 21, 2018 - Overuse of antibiotics not what the doctor ordered
July 21, 2018 - Bundled-payment system did not lower costs for serious medical conditions, shows study
July 21, 2018 - Therapy dogs found to be effective in reducing ADHD symptoms in children
July 21, 2018 - Could rotating multiple therapists better treat PTSD patients?
July 21, 2018 - Binge drinking impairs working memory in adolescent brain
July 21, 2018 - Dying at home could be beneficial for terminally ill cancer patients and their relatives
July 21, 2018 - Researchers identify subtypes of retinal ganglion cells using single-cell RNA sequencing
July 21, 2018 - Study uncovers opportunities to reduce death by suicide among cancer patients
July 21, 2018 - Genetic sequencing reveals new clues to aggressiveness of prostate cancer
July 21, 2018 - BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
July 21, 2018 - First major study comparing robotic to open surgery published in The Lancet
July 21, 2018 - ADHD medications may fail to improve cognition in healthy college students, study shows
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Using tendon transfer surgery to restore key functions in spinal cord injury patient
July 21, 2018 - Scientists create wearable device that measures cortisol in sweat
July 21, 2018 - Researchers study efficacy and safety of new treatment for OUD
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Study examines effects of a two-day intermittent calorie restriction diet for patients with type 2 diabetes
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
Two immunotherapy approaches for multiple myeloma show hope

Two immunotherapy approaches for multiple myeloma show hope

image_pdfDownload PDFimage_print

Researchers from the University of Pennsylvania’s Abramson Cancer Center have developed two experimental immunotherapy methods that include one chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma patients who were not responding to other treatments.

Multiple myeloma is a cancer of the bone marrow. healthy plasma cells in the bone marrow mutate and multiply uncontrollably. malignant plasma cells produce a paraprotein. Image Credit: Designua / Shutterstock

Multiple myeloma is a cancer of the bone marrow. healthy plasma cells in the bone marrow mutate and multiply uncontrollably. malignant plasma cells produce a paraprotein. Image Credit: Designua / Shutterstock

The other study used a monoclonal antibody in treatment of multiple myeloma. Both of the studies would be presented as oral abstracts at the 59th Annual American Society of Hematology Meeting and Exposition in Atlanta.

The team of researchers administered CAR T cells to the multiple myeloma patients after they had undergone chemotherapy and found that 64 percent of the patients responded favorably after the therapy. In the other study an experimental monoclonal antibody was infused into patients with resistant multiple myeloma and an overall response rate of 60 percent was noted. According to the researchers that receptor targeted in both these immunotherapy approaches is called the B-Cell Maturation Antigen (BCMA). BCMA occurs in high abundance in patients with myeloma and thus can be used as a target for these drugs in multiple myeloma.

Multiple myeloma affects thousands of patients every year. According to the American Cancer Society the estimated number of new cases this year is around 30,200 and these patients are usually treated with chemotherapy, radiation therapy and stem cell transplant. Multiple myeloma affects particular immune cells called the plasma cells that become cancerous and multiply uncontrollably.

Study 1

The first study is presented as Abstract #505 which involves the use of CART-BCMA. Here the CAR T cells are developed specially by the researchers in collaboration with Novartis over the past five years. Patient’s own immune cells are collected and they are modified in such a manner so that they can find and destroy the cancer cells specifically. These are termed “hunter” cells that can target the BCMA receptor that is present over the cancer cells and can multiply within the body to kill the cancer cells. The normal white blood cells are suppressed first using a chemotherapy cycle before infusing these CAR-T cells. The patients included in the experimental clinical trial had all failed with traditional treatment before being enrolled for the study. On an average they had received some seven lines of therapy before this study and failed to respond adequately.

The group was divided into two dose groups of the CART-BCMA therapy – the lower dose included 5 patients and the higher dosage group had 10 patients. The lower dosage group showed minor response in at least 2 patients. Minor response was defined as 25 percent or more reduction in the levels of myeloma protein. In the higher dosage group, minor response was seen in eight patients (80 percent) and one patient showed complete response. The clinical trial is not yet concluded and more patients are being treated with the higher dose level. Of the 15 patients, side effects such as cytokine-release syndrome which manifests as flu like syndrome, nausea, fever, muscle pain etc. was noted in 12 patients. For this side effect one patient received tocilizumab and another received siltuximab as therapy. No deaths were seen during the study and three patients developed some nerve toxicity that did not persist. Study’s lead author Adam D. Cohen, assistant professor of Hematology and Oncology at Penn and the director of Myeloma Immunotherapy in Penn’s Abramson Cancer Center emphasized the importance of BCMA as an important target in treating multiple myeloma. The study was supported by the Penn-Novartis alliance.

Study 2

The second study presented as Abstract #741 used an experimental drug called GSK2857916. Dr. Cohen led this study as well. This new experimental drug was given breakthrough therapy designation by the US FDA this November so that it could be developed in an expedited fashion. This drug is combination of a chemotherapy drug called MMAF and a monoclonal antibody that targets the BCMA.

For the trial, 35 patients were given 16 treatment cycles with this experimental drug every three weeks. At the end of the study, 21 out of 35 (60 percent) showed some response to the drug. Around 51 percent showed a good partial response which meant that their myeloma protein levels reduced by over 90 percent. Media time that the patient spent without the disease progressing was around eight months.

Significant side effects in this study included eye toxicities such as dry eyes and blurry vision that was seen in 63 percent patients. Cohen added that there was a high response rate which had never been seen among these cases which were unresponsive to routine treatments.

Tagged with:

About author

Related Articles